Micro Labs’ Carsyon division has launched a new statin molecule, rosuvastatin 10 mg tablets, under the brand name Turbovas. Rosuvastatin is considered as a step ahead in lipid control.

The division already has a strong presence in the statin market with two major brands, Avas (atorvastatin) and Simvas (simvastatin). With the launch of Turbovas, Carsyon division is expanding its horizons in the Rs.153-crore statins’ market growing at a rate of 23%, compared to the cardiovascular market’s growth of 13 percent, said G.N.Suresha, general manager, sales & marketing. Caryson, Micro Labs.

The new statin has been demonstrated to reduce the LDC-C, a major culprit in coronary artery disease (CAD), more efficiently than existing statins, and does not require upward dosage titration in the majority of patients, he explained.

Rosuvastatin will be a great boon not only to CAD-prone patients but also to the industry in boosting its market share in the potentially promising statin market.

Carsyon division is expected to touch a sales figure of around Rs.90 crore in the current financial year, with an expected growth of 40 per cent over last year, informed Suresha.